within Pharmacolibrary.Drugs.ATC.D;

model D06BA06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 0.0003333333333333333,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008333333333333333,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>D06BA06</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Sulfamerazine is a sulfonamide antibiotic, formerly widely used for the treatment of bacterial infections such as urinary tract infections and some skin infections. It is part of the sulfonamide class which inhibits bacterial folic acid synthesis. Due to the development of resistance and safer alternatives, sulfamerazine is rarely used in clinical practice today in humans but may still have occasional veterinary applications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adult subjects based on analogy with other sulfonamides, since there are no primary published PK studies of sulfamerazine itself in indexed literature. Estimates are based on similar drugs in class such as sulfamethazine and sulfadiazine.</p><h4>References</h4><ol><li><p>Hayashi, M, et al., &amp; Koritz, GD (1979). Disposition of sulfonamides in food-producing animals: pharmacokinetics of sulfamerazine in ewe lambs. <i>American journal of veterinary research</i> 40(11) 1578–1582. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/525876/\">https://pubmed.ncbi.nlm.nih.gov/525876</a></p></li><li><p>De Backer, P, et al., &amp; Debackere, M (1982). Pharmacokinetics of sulfamerazine and antipyrine in neonatal and young lambs. <i>American journal of veterinary research</i> 43(10) 1744–1751. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7149373/\">https://pubmed.ncbi.nlm.nih.gov/7149373</a></p></li><li><p>Huttunen, KM, et al., &amp; Rautio, J (2009). The first bioreversible prodrug of metformin with improved lipophilicity and enhanced intestinal absorption. <i>Journal of medicinal chemistry</i> 52(14) 4142–4148. DOI:<a href=\"https://doi.org/10.1021/jm900274q\">10.1021/jm900274q</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19522462/\">https://pubmed.ncbi.nlm.nih.gov/19522462</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end D06BA06;
